Centogene enrolls first patient in frontotemporal dementia (ftd) clinical study

Cambridge, mass. and rostock, germany and berlin, oct. 28, 2021 (globe newswire) -- centogene n.v. (nasdaq: cntg), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced today that the first patient has been enrolled in the international efront study, an observational study to understand the prevalence of genetic mutations in patients with frontotemporal dementia (ftd).
CNTG Ratings Summary
CNTG Quant Ranking